Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Inflamm Bowel Dis. 2011 Aug 29;18(4):613–623. doi: 10.1002/ibd.21843

Figure 2.

Figure 2

Microscopic appearance of representative trichrome stained sections of cecum from HSA-injected control rats (A,B), PG-PS-injected rats (vehicle treated; C-F), and PG-PS-injected rats treated with resveratrol 100/mg/kg/d (G,H). A, C, and G are X40 original magnification photomicrographs of cecum from HSA-injected control rats, PG-PS-injected rats (vehicle treated), and PG-PS-injected rats treated with resveratrol, respectively. B, D-F, and H are X100 original magnification photomicrographs of cecum from HSA-injected control rats, PG-PS-injected rats (vehicle treated), and PG-PS-injected rats treated with resveratrol, respectively. PGPS-injected (vehicle treated) rats have dense collagen (stained blue) expanding the submucosa and disrupting the muscularis externa (muscularis externa in brackets in C and F; disruption indicated by an arrow). Mucosal inflammation is shown in brackets in E; the insert is X200 original magnification of a crypt abscess. PG-PS-injected (vehicle treated) rats have granulomas in the submucosa, many of which are necrotizing (asterisk in D). PG-PS-injected rats treated with resveratrol 100/mg/kg/d (G,H) have less collagen in the submucosa and serosa, and the integrity of the muscularis externa is generally maintained compared with that of the PG-PS- injected (vehicle treated) rats. The brackets in H indicate foamy histiocytes in the submucosa in the PG-PS-injected rats treated with resveratrol.